JB-102

JB-102 is a preclinical-stage cell therapy being developed by Junten Bio for the induction of immune tolerance in patients undergoing liver or kidney transplantation. As part of Junten Bio's research into organ transplant tolerance, JB-102 is designed to modulate the recipient's immune system to prevent graft rejection, potentially reducing or eliminating the requirement for chronic immunosuppressive therapy. While specific details regarding its cellular composition and molecular targets are not as extensively disclosed as the lead candidate JB-101 (which utilizes induced suppressor T cells), JB-102 represents an expansion of the company's cell therapy platform targeting intractable diseases caused by hyperimmune reactions.